Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency.
The efficacy of a live, oral, pentavalent rotavirus vaccine against G1-4 rotavirus gastroenteritis (RVGE) was retrospectively assessed based on breastfeeding frequency among 5098 infants in a placebo-controlled trial. The efficacy against any RVGE severity for infants never breastfed, sometimes breastfed, or exclusively breastfed was 68.3%, 82.2%, and 68.0%, respectively. The efficacy against severe RVGE was 100%, 95.4%, and 100%, respectively. Breastfeeding did not seem to adversely impact the efficacy of pentavalent rotavirus vaccine.
From Merck & Co., Inc., West Point, PA, USA.
Michelle G
MG
Goveia
Mark J
MJ
DiNubile
Michael J
MJ
Dallas
Penny M
PM
Heaton
Barbara J
BJ
Kuter
D001942:Breast Feeding / Q000706:statistics & numerical data*; D005759:Gastroenteritis / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D010919:Placebos / Q000008:administration & dosage; D016865:Reassortant Viruses / Q000276:immunology*; D012189:Retrospective Studies; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000276:immunology*
D010919:Placebos; D022243:Rotavirus Vaccines